Health · 1 sources covering this

STAT+: Anthropic joins ARPA-H clinical AI moonshot, will hold closed-door health care event

In this edition of STAT Health Tech: Oura delays IPO plans, Anthropic joins an clinical AI effort by ARPA-H, and MAHA's health data goals.

Share:X WhatsApp Reddit Facebook LinkedIn Open ↗

Coverage spectrum

0 L · 1 C · 0 R

How 1 sources are covering this

STATCenter·1h ago
STAT+: Anthropic joins ARPA-H clinical AI moonshot, will hold closed-door health care event
In this edition of STAT Health Tech: Oura delays IPO plans, Anthropic joins an clinical AI effort by ARPA-H, and MAHA's health data goals.
Read at STAT →

Embed this bias spectrum on your site

Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.

<iframe
  src="https://statesidedaily.com/embed/cluster/f3e09cfc37854edc76e7da8d286387fc5e5a8b22"
  width="100%" height="320"
  style="border:0;max-width:680px"
  loading="lazy"
  title="STAT+: Anthropic joins ARPA-H clinical AI moonshot, will hold closed-door health care event"></iframe>

STAT+: Anthropic joins ARPA-H clinical AI moonshot, will hold closed-door health care event

How 1 sources are covering this

STAT+: Anthropic joins ARPA-H clinical AI moonshot, will hold closed-door health care event

More from Health

STAT+: AstraZeneca invests $2 billion in Summit Therapeutics

STAT+: Pharmalittle: We’re reading about Novo licensing a Chinese obesity pill, Merck pulling an antibiotic, and more

Researchers slow neurodegeneration in mice by barring T cells from the brain

STAT+: UniQure’s gene therapy continues to slow Huntington’s progression after four years

Reader

Trust & legal

Across the network

How 1 sources are covering this

STAT+: Anthropic joins ARPA-H clinical AI moonshot, will hold closed-door health care event

More from Health

STAT+: AstraZeneca invests $2 billion in Summit Therapeutics

STAT+: Pharmalittle: We&#8217;re reading about Novo licensing a Chinese obesity pill, Merck pulling an antibiotic, and more

Researchers slow neurodegeneration in mice by barring T cells from the brain

STAT+: UniQure&#8217;s gene therapy continues to slow Huntington&#8217;s progression after four years

Reader

Trust & legal

Across the network

STAT+: Pharmalittle: We’re reading about Novo licensing a Chinese obesity pill, Merck pulling an antibiotic, and more

STAT+: UniQure’s gene therapy continues to slow Huntington’s progression after four years